Page last updated: 2024-12-08

3'-(1-butylphosphoryl)adenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3'-(1-butylphosphoryl)adenosine: regulatory substance inducing production of rifamycin in Nocardia sp; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID171147
SCHEMBL ID2239470
MeSH IDM0129994

Synonyms (7)

Synonym
3'-adenylic acid, monobutyl ester
[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] butyl hydrogen phosphate
3'-(1-butylphosphoryl)adenosine
b-factor
52278-63-4
SCHEMBL2239470
DTXSID40200305

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The frequencies of reactogenicity and adverse events after each dose were recorded in the safety population (all participants who received at least one dose and had safety data available)."( Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.
Anderson, AS; Balmer, P; Beeslaar, J; Jiang, HQ; Maansson, R; Maguire, JD; Marshall, HS; O'Neill, R; Perez, JL; Prégaldien, JL; Richmond, PC; Szenborn, L; Vesikari, T; Wysocki, J, 2023
)
0.91
" Adverse event frequency was similar between the MenB-FHbp and control groups and less frequent following MenB-FHbp booster than following primary doses."( Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.
Anderson, AS; Balmer, P; Beeslaar, J; Jiang, HQ; Maansson, R; Maguire, JD; Marshall, HS; O'Neill, R; Perez, JL; Prégaldien, JL; Richmond, PC; Szenborn, L; Vesikari, T; Wysocki, J, 2023
)
0.91
" These findings support a favourable MenB-FHbp immunogenicity and reactogenicity profile in young children, a population at increased risk of adverse invasive meningococcal disease outcomes."( Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.
Anderson, AS; Balmer, P; Beeslaar, J; Jiang, HQ; Maansson, R; Maguire, JD; Marshall, HS; O'Neill, R; Perez, JL; Prégaldien, JL; Richmond, PC; Szenborn, L; Vesikari, T; Wysocki, J, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (58.06)18.7374
1990's2 (6.45)18.2507
2000's1 (3.23)29.6817
2010's3 (9.68)24.3611
2020's7 (22.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.71 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.13%)5.53%
Reviews2 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (90.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]